ALLERGAN (COSTA RICA)

What the Data Shows About ALLERGAN (COSTA RICA)

ALLERGAN (COSTA RICA) is associated with 169,927 adverse-event reports in the FDA Manufacturer and User Facility Device Experience (MAUDE) database , spanning reports dated from 2011 through 2026. Of the total, 64 are coded as death reports and 168,811 as injury reports, with the remainder classified as malfunctions or other event types. These counts reflect reports submitted to the FDA by manufacturers, healthcare facilities, and patients — they are raw signal, not adjudicated safety findings, and higher-volume manufacturers or older product portfolios naturally generate larger raw counts.

The reports span 8 distinct device types attributed to this manufacturer in MAUDE, which means any safety read for ALLERGAN (COSTA RICA) should be reviewed at the device-family level rather than company-wide. Across those devices, 3 distinct event types appear in the record, led by Injury at 168,811 reports (99.3% of total). Patient-outcome categorizations are reported across 15 distinct outcomes, giving a shaped distribution rather than a single headline figure.

Year-over-year reporting volume is tracked across 15 years of MAUDE data, with the peak single-year volume reaching 26,414 reports — trend shape can reflect shifts in device sales, FDA reporting requirements, or post-market recall activity as much as intrinsic device performance. The MAUDE system is one input among many in FDA post-market surveillance and does not draw safety conclusions from individual submissions. All figures reflect the openFDA snapshot refreshed on 2026-05-15, and nothing on this page is medical or regulatory advice — consult a qualified clinician or the FDA for current safety communications.